Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Daliresp, Daxas
Roflumilast is a selective phosphodiesterase-4 (PDE4) inhibitor indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis in adult patients with a history of exacerbations. It works by reducing inflammation in the airways, helping to improve lung function and reduce the frequency of exacerbations.
For maintenance treatment of chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations in adults.
Suicidal thoughts or behavior.
Outcome:
Increased risk of theophylline toxicity.
Mechanism:
Both drugs are metabolized by CYP1A2 and 3A4.
Outcome:
Increased roflumilast plasma levels.
Mechanism:
Erythromycin inhibits CYP3A4.
Outcome:
Potentially increased caffeine levels.
Mechanism:
Roflumilast may inhibit CYP1A2.
Most likely new formulation: Controlled-release formulation (2025, 60% confidence)
Based on current usage trends and clinical trial data, there is a 75% likelihood that roflumilast will maintain its current regulatory status for the next 5 years.
Phosphodiesterase-4 (PDE4) Inhibitor
Phosphodiesterase-4 Inhibitor